Akebia Therapeutics (AKBA) Net Cash Flow (2013 - 2026)

Akebia Therapeutics (AKBA) has 14 years of Net Cash Flow data on file, last reported at -$22.2 million in Q1 2026.

• Net Cash Flow for Q1 2026 came in at -$22.2 million, down 136.08% year-over-year; the trailing twelve-month figure through Mar 2026 was $49.3 million (down 31.0% YoY), and the FY2025 annual result was $133.0 million, up 1382.48% from the prior year.
• Net Cash Flow fell to -$22.2 million in Q1 2026 per AKBA's latest filing, from $18.4 million in the prior quarter.
• Over five years, Net Cash Flow peaked at $61.5 million in Q1 2025 and troughed at -$54.7 million in Q4 2022.
• A 5-year average of $735823.5 and a median of -$2.5 million in 2024 frame the typical range for Net Cash Flow.
• The sharpest annual moves came in 2023 and 2025: Net Cash Flow tumbled 919.93% in 2023, then jumped 6527.27% in 2025.
• A 5-year view of Net Cash Flow shows it stood at -$54.7 million in 2022, then jumped by 93.42% to -$3.6 million in 2023, then soared by 596.3% to $17.9 million in 2024, then grew by 3.06% to $18.4 million in 2025, then sank by 220.6% to -$22.2 million in 2026.
• Business Quant data shows AKBA's Net Cash Flow at -$22.2 million in Q1 2026, $18.4 million in Q4 2025, and $29.1 million in Q3 2025.